Autoimmune Diseases: Systemic and Oral Health Considerations. Ann Eshenaur Spolarich, RDH, PhD
|
|
- Baldwin Walker
- 6 years ago
- Views:
Transcription
1 COURSE TITLE: COURSE INSTRUCTOR: COURSE CREDITS: Autoimmune Diseases: Systemic and Oral Health Considerations JoAnn R. Gurenlian, RDH, PhD and Ann Eshenaur Spolarich, RDH, PhD 2 CEUs COURSE DATE: August 1, 2012 COURSE DESCRIPTION: Approximately 2% of the population suffers from autoimmune disease and most of these individuals are women. The diseases themselves, as well as the medication management, can adversely affect the oral cavity and significantly impact quality of life. This course will highlight common autoimmune diseases, oral and systemic disease manifestations, and appropriate dental hygiene interventions. LEARNING OBJECTIVES: Upon completion of this continuing education course, the participant will be able to: 1. Describe the pathophysiology of immune system dysfunction. 2. Identify common signs and symptoms of various autoimmune diseases. 3. Discuss the classes of drugs that are frequently used to treat autoimmune diseases. 4. Identify oral manifestations of common autoimmune diseases. 5. Recognize the adverse oral and systemic complications associated with medications used to treat autoimmune diseases. 6. Discuss the effects of chronic steroid use on the human body. 7. Identify important practice management considerations when planning dental hygiene care for patients with autoimmune disease. 8. Deliver dental hygiene services safely and effectively for patients with autoimmune disease. *This material is the intellectual property of the authors and may not be reproduced or distributed without their written permission. 1
2 CASE STUDY #1 Ruth Burkowski is a 43 year old female who presents with a complicated medical history. She was diagnosed two years ago with Systemic Lupus Erythematosis (SLE( and Rheumatoid Arthritis (RA). It took almost 3 years to diagnose her SLE condition. She has a family history of CVD and arthritis. Her father died of a pulmonary infection and her mother of TB. Her older brother died of brain cancer, and her younger brother has a history of Sjögren s Syndrome. She states that her mother told her she had an allergic reaction to penicillin as a child, but she has no recollection of this episode as she was very young when it occurred. Ruth is presently under the care of a rheumatologist who coordinates her medical treatment with a cardiologist and an endocrinologist. She attends regular dental hygiene appointments every 3 months and has a significant dental history of caries, episodic gingivitis, and fractured teeth requiring both endodontic and restorative treatment. Identify the significant aspects of Ruth s medical and dental history. What follow-up questions would you ask Ruth? What are symptoms of RA? What are symptoms of SLE? What are the oral signs of SLE? What medications are used to treat these conditions? What are the side effects of these medications? 2
3 DRUGS FOR AUTOIMMUNE DISEASE MANAGEMENT RHEUMATOID ARTHRITIS IS THE PHARMACOLOGIC MODEL: Goals of therapy are palliative o Reduce joint inflammation and swelling o Relieve pain and stiffness o Encourage normal function Aspirin and NSAIDS are cornerstones of treatment o Reduce inflammation (swelling), pain and fever Adverse Effects of Aspirin o Adverse gastrointestinal effects Ulceration and bleeding o Effects on the kidney Retention of sodium and water May cause hyperkalemia and edema in some patients o Special senses adverse effects Tinnitus is sign of toxicity to aspirin Requires decrease in dose o Respiratory system Toxic levels may cause central respiratory paralysis = respiratory acidosis NSAIDS o ibuprofen (Motrin, Advil, Rufen, Nuprin) o naproxen (Naprosyn, Aleve) o sulindac (Clinoril) o tolmetin (Tolectin) o fenoprofen (Nalfon) o piroxicam (Feldene) o diclofenac (Voltaren) o flurbiprofen (Ansaid) o diflunisal (Dolobid) o etodolac (Lodine) o nabumetone (Relafen) Oral Complications of Aspirin and NSAIDS o Prolonged bleeding Usually not clinically significant Control with local hemostatic agents as needed o Oral aphthous ulceration/aphthous stomatitis 3
4 sulfasalazine (Azulfidine) Salicylate: 5-aminosalicylic acid Interferes with prostaglandin synthesis Used for treatment of RA in patients with inadequate response to aspirin and NSAIDS Side effects: headache, photosensitivity, GI distress, anorexia COX-2 Inhibitors = celebrex (Celecoxib) Contraindicated in aspirin/nsaid allergic patients (cross-sensitivity) Celebrex is contraindicated in those allergic to sulfonamides Multiple drug interactions OK to use with low dose aspirin Adverse cardiovascular risks: o Increased risk for stroke o Monitor patient s blood pressure when used with antihypertensives = decrease effectiveness of BP meds o Increased risk for heart attack Unanticipated bleeding may occur o Assess bleeding times when used with warfarin DMARDS = Disease-modifying anti-rheumatic drugs *Also known as SAARDS = slow-acting Used for treatment of RA and OA Potential to reduce or prevent joint damage Used for patients who do not respond to COX-2 inhibitors Slow course of disease = may induce remission Prevent further destruction of joints/tissues Slow onset of action o May take 3 to 4 months to see effects Preparations (subfamilies of DMARDS): o Immune modulators methotrexate, leflunomide Anticytokine therapies etanercept, infliximab, adalimumab, anakinra o Antimalarials Chloroquine, hydroxychloroquine o Penicillamine o Gold compounds 4
5 IMMUNE MODULATORS *methotrexate (Rheumatrex, Trexall) = also used for chemotherapy Used alone or in combination with other DMARDS *Drug of choice for severe RA or psoriatic arthritis (especially when unresponsive to NSAIDS) Slows appearance of new erosions within involved joints Response within 3-6 weeks of starting treatment o Faster effect than other DMARDS Adverse effects of methotrexate: o Dose is lower than for chemotherapy, so fewer side effects o Most common: mucosal ulcerations, nausea o Side effects with chronic use: Cytopenias depression of WBC count Cirrhosis of liver Acute pneumonia-like syndrome leflunomide (Arava) Mechanism: anti-proliferative and anti-inflammatory effects Reduces pain and inflammation Slows progression of structural damage Adverse Effects of leflunomide (Arava) o Most common: headache, diarrhea, nausea o Other: Weight loss Allergic reactions Flu-like syndrome Skin rach Alopecia Hypokalemia Teratogenic = contraindicated in pregnant women and women of child-bearing years Hepatotoxic ANTICYTOKINE THERAPIES Interleukin-1b and tumor necrosis factor alpha are proinflammatory cytokines involved in pathogenesis of RA When secreted by synovial macrophages, IL-1b and TNF alpha stimulate synovial cells to proliferate and synthesize collagenase, which degrades cartilage, stimulates bone resorption and inhibits proteoglycan synthesis Drug antagonists (blockers) to these cytokines are effective in treating RA 5
6 etanercept (Enbrel) TNF alpha blocker o Binds to TNF molecules and blocks interaction with cell surface receptors Indicated for moderate to severe RA May affect defenses against infections and malignancies Risk for activation of hepatitis and tuberculosis in carriers Given subcutaneously Side effects: headache, injection site reaction, upper respiratory tract infections infliximab (Remicade) TNF alpha blocker Inhibits progression of structural damage and improves physical function in patients with moderate to severe disease Long-term use is associated with developing antibodies against the drug, unless the drug is combined with methotrexate Side effects: infections leading to pneumonia, cellulitis; blood dyscrasias adalimumab (Humira) TNF alpha blocker o Recombinant monoclonal antibody that binds to TNF alpha receptor sites Treatment of moderate to severe RA in patients with inadequate response to one or more DMARDS Decreases signs and symptoms, and structural damage Subcutaneous administration only Side effects: headache, nausea, rash, injection site reaction anakinra (Kineret) Interleukin-1 receptor antagonist (blocker) Treatment of moderate to severe RA in patients who have failed one or more DMARDS Slows degradation of cartilage and bone loss Side effects: headache, injection site reaction, infections ANTIMALARIALS Preparations: chloroquine (Aralen); hydroxychloroquine (Plaquenil) Treatment of RA that is unresponsive to NSAIDS o May be used in combination with aspirin and/or corticosteroids Slow progression of erosive bone lesions May induce remission 6
7 Severe side effects/toxicity: o severe eye damage o *blue-black intraoral pigmentation CHELATING AGENT penicillamine (also used as antidote for heavy metal poisoning) Slows the progression of bone destruction and RA Mechanism: depresses circulating IgM rheumatoid factor, depresses T-cell activity Used for RA treatment after gold salts have failed, but before use of corticosteroids Side effects: dermatologic, nephritis, aplastic anemia Oral Complications with Penicillamine o Infection o Delayed healing o Prolonged bleeding o Oral ulcerations GOLD COMPOUNDS Decrease inflammation Slows progression of bone and articular destruction Mechanism: (exact is unknown) o Taken up by macrophages causing inhibition of phagocytosis and lysosomal membrane stabilization o Decreased serum rheumatoid factor o Alterations in immunoglobulins o Decreased complement activation o Inhibition of prostaglandin synthesis o Decreased lysosomal enzyme activity Preparations: expensive to buy and administer o aurothioglucose o auranofin (Ridaura) o gold sodium thiomalate (Aurolate) High incidence of toxicity = requires intensive monitoring o Dermatitis with mucosal ulcerations o Proteinuria o Neutropenia o Thrombocytopenia Oral Complications with Gold o Infection o Delayed healing 7
8 o Prolonged bleeding o Glossitis o Aphthous stomatitis o Blue-black intraoral pigmentation IMMUNOSUPPRESSIVE DRUGS Used in cases of refractory RA o azathioprine (Imuran, Azasan) o cyclophosphamide (Cytoxan) o cyclosporine (Sandimmune, Gengraf, Neoral, Restasis) azathioprine (Imuran, Azasan) Immunosuppressant Also an antineoplastic drug for cancer therapy Used also in dentistry with prednisone for severe erosive lichen planus, major aphthous stomatitis, erythema multiforme, benign mucous membrane pemphigoid Side effects: fever, malaise, alopecia, rash, GI, blood dyscrasias, hepatotoxic cyclophosphamide (Cytoxan) Immunosuppressant Also an antineoplastic drug for cancer therapy Used for severe RA Side effects: alopecia, infertility, GI, blood dyscrasias cyclosporine (Sandimmune, Gengraf, Neoral, Restasis) Immunosuppressant Used primarily to prevent rejection of organ transplants Used for severe active RA that is not responsive to methotrexate Inhibition of production and release of interleukin II and inhibits interleukin IIinduced activation of resting T lymphocytes Side effects: o Headache, hypertension, hirsuitism, GI, tremor, renal toxicity, gingival hyperplasia ( <16% of users) CORTICOSTEROIDS Synthetic Glucocorticoid Medications Indicated for: o Autoimmune diseases o Immunosuppressive therapy in organ transplant patients o Respiratory disease management o In dentistry: For reduction of pain and swelling Treatment of inflammatory pathologies of oral mucosa 8
9 Potency Each steroid is rated as to potency as compared to a hydrocortisone equivalent dose The more potent the drug: o the lower the dose o the higher the risk for adrenal suppression Topical applications least likely to cause adrenal suppression (except those with high potency) Systemic steroids more likely to cause adrenal suppression Compound Potency Equivalent Dose (mg) Short-Acting < 12 hours Cortisol 1 20 Cortisone Intermediate-Acting hours Prednisone 4 5 Prednisolone 4 5 Methylprednisolone 5 4 Triamcinolone 5 4 Long-Acting > 36 hours Paramethasone 10 2 Betamethasone Bexamethasone Dosing Considerations with Steroids Drugs are taken in the morning Alternate day therapy Lengthening interval between dosing allows for same effects with fewer side effects Adrenal gland functions normally on off day HPA axis not suppressed; less risk for adrenal suppression Alternate day therapy is used for patients who must take steroids for longer than 1 month 9
10 Dosing Considerations with Steroids Daily therapy poses greater risk for adrenal suppression Chronic steroid users wean off steroids in descending doses (tapered dosing) Normal adrenal output of cortisol = mg hydrocortisone equivalent Any medication dosage that exceeds this amount may cause suppression During stress, adrenals may secrete up to 300 mg of hydrocortisone equivalent DETERMINING NEED FOR STERIOD SUPPLEMENTATION Patients with past history of steroid use Medical history interview Determine if steroids used within past 2 weeks Reason for stopping? (previous indication) Type, dose and duration of therapy Look for signs/symptoms of adrenal insufficiency Identify dental treatment needs Routine dental care No supplementation necessary Major invasive oral surgical procedure Physician consultation, Laboratory testing Patients Currently Taking Steroids Medical history interview Dose and duration of systemic steroid use Identify signs/symptoms of possible insufficiency For diagnostic and minimally invasive procedures: Patient takes usual daily dose Schedule patient first thing in morning Stress reduction protocol Pain control Anxiety control Monitor blood pressure For major invasive procedures (oral surgery) Physician consultation Laboratory testing Steroid supplementation as needed Steroid Supplementation in Dentistry Routine dental procedures (excluding extractions) Patients currently taking steroids None Use good pain and anxiety control 10
11 Patients with history of regular steroid use none Patients using topical or inhaled steroids none Complications of Chronic Steroid Use Insomnia Peptic ulceration (watch NSAIDS) Osteoporosis Cataract formation Glaucoma Growth suppression Delayed wound healing Oral Side Effects of Steroid Use Candidiasis = most common Patients using inhalers Use topical antifungal therapy Poor wound healing = long-term use Masking of oral infections = anti-inflammatory Xerostomia = inhaled and systemic steroids Power-assisted devices Fluorides SUGGESTED RESOURCES Little JW, Falace DA, Miller CS, Rhodus NL. Dental Management of the Medically Compromised Patient. 7 th ed. St. Louis: Mosby Elsevier, Pickett FA, Terezhalmy GT. Dental Drug Reference with Clinical Implications. 2 nd ed. Baltimore, Lippincott Williams & Wilkens, Wynn RL, Meiller TF, Crossley HL. Drug Information Handbook in Dentistry. 17 th ed. Hudson, Lexi-Comp Inc.,
Regulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 9 Last Review Date: March 16, 2018 Simponi / Simponi
More informationCimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.11 Section: Prescription Drugs Effective Date: April 1, 2018 Subject: Cimzia Page: 1 of 5 Last Review
More informationSalicylates: Interactions 10/14/2009. Salicylates DRUGS USED IN THE MANAGEMENT OF MUSCULOSKELETAL DISORDERS. Chapters 17, 18, 34 & Pages 577 &
DRUGS USED IN THE MANAGEMENT OF MUSCULOSKELETAL DISORDERS Chapters 17, 18, 34 & Pages 577 & 579-586 Salicylates aspirin Have analgesic, antipyretic, and anti-inflammatory effects. Inhibits the production
More informationMUSCULOSKELETAL PHARMACOLOGY. A story of the inflamed
MUSCULOSKELETAL PHARMACOLOGY A story of the inflamed 1 INFLAMMATION Pathophysiology Inflammation Reaction to tissue injury Caused by release of chemical mediators Leads to a vascular response Fluid and
More informationCIMZIA (certolizumab pegol)
Pre - PA Allowance None Prior-Approval Requirements Age Diagnoses 18 years of age or older Patient must have ONE of the following: 1. Moderate to severe Crohn s Disease (CD) a. Inadequate response, intolerance
More informationRheumatoid arthritis
Rheumatoid arthritis 1 Definition Rheumatoid arthritis is one of the most common inflammatory disorders affecting the population worldwide. It is a systemic inflammatory disease which affects not only
More informationNSAIDs. NSAIDs are important but they can have side effects.
NSAIDs Pain Treatment Nonsteroidal anti-inflammatory drugs (NSAIDs) are often recommended for initial treatment of pain and can be added to more powerful drugs to treat worse pain. Acetaminophen, such
More informationRheumatoid Arthritis
Rheumatoid Arthritis Rheumatoid Arthritis (RA) is a form of arthritis characterized by swelling and pain in the joints. If severe enough RA can also affect people s internal organs. RA is considered an
More informationImmune Modulating Drugs Prior Authorization Request Form
Patient: HPHC member ID #: Requesting provider: Phone: Servicing provider: Diagnosis: Contact for questions (name and phone #): Projected start and end date for requested Requesting provider NPI: Fax:
More informationStelara. Stelara (ustekinumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.04 Subject: Stelara Page: 1 of 9 Last Review Date: September 20, 2018 Stelara Description Stelara
More informationAntirheumatic drugs. Rheumatic Arthritis (RA)
Antirheumatic drugs Rheumatic Arthritis (RA) Disease Modifying Antirheumatic drugs (DMARDs) DMARDs are used in the treatment of rheumatic arthritis RA and have been shown to slow the course of the disease,
More informationACTEMRA (tocilizumab)
Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following: 1. Active Polyarticular Juvenile Idiopathic Arthritis (PJIA) b. Patient has an intolerance or has experienced
More informationXeljanz. Xeljanz, Xeljanz XR (tofacitinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.24 Subject: Xeljanz Page: 1 of 6 Last Review Date: March 16, 2018 Xeljanz Description Xeljanz, Xeljanz
More informationOtezla. Otezla (apremilast) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Otezla Page: 1 of 5 Last Review Date: March 16, 2018 Otezla Description Otezla (apremilast) Background
More informationMMS Pharmacology Lecture 2. Antirheumatic drugs. Dr Sura Al Zoubi
MMS Pharmacology Lecture 2 Antirheumatic drugs Dr Sura Al Zoubi Revision Rheumatoid Arthritis Definition (RA): is the most common systemic inflammatory disease characterized by symmetrical inflammation
More informationCosentyx. Cosentyx (secukinumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.11 Subject: Cosentyx Page: 1 of 7 Last Review Date: September 20, 2018 Cosentyx Description Cosentyx
More informationRegulatory Status FDA-approved indication: Orencia is a selective T cell co-stimulation modulator indicated for: (1)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Orencia Page: 1 of 9 Last Review Date: September 20, 2018 Orencia Description Orencia (abatacept)
More informationBirthdate: / / Address: Age: Sex: M F. Telephone: H ( ) City State Zip W ( ) C ( )
Please complete this questionnaire in its entirety, even if you feel some questions may not apply to you. Our staff is available should you have any questions, or need assistance with the completion of
More informationDrug Therapy Today in Rheumatic Diseases
Drug Therapy Today in Rheumatic Diseases Piotr Leszczynski,, MD, PhD,, CCD A wide range of drugs are currently avaiable for rheumatic diseases Analgesic drugs (acetaminophen, opioids) NSAIDs (analgesic
More informationCorticosteroids. Abdulmoein Al-Agha, FRCPCH Professor of Pediatric Endocrinology, King Abdulaziz University Hospital,
Corticosteroids Abdulmoein Al-Agha, FRCPCH Professor of Pediatric Endocrinology, King Abdulaziz University Hospital, http://aagha.kau.edu.sa History 1855 Addison's disease 1856 Adrenal glands essential
More informationSubject: Remicade (Page 1 of 5)
Subject: Remicade (Page 1 of 5) Objective: I. To ensure that Health Share/Tuality Health Alliance (THA) has a process by which the appropriate utilization of Remicade (Infliximab) for members whose diagnosis
More informationImmunosuppressants. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Immunosuppressants Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Immunosuppressive Agents Very useful in minimizing the occurrence of exaggerated or inappropriate
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: golimumab_simponi 8/2013 2/2018 2/2019 3/2018 Description of Procedure or Service Golimumab (Simponi and
More informationActemra. Actemra (tocilizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.12 Subject: Actemra Page: 1 of 13 Last Review Date: September 20, 2018 Actemra Description Actemra
More informationPatient #1. Rheumatoid Arthritis. Rheumatoid Arthritis. 45 y/o female Morning stiffness in her joints >1 hour
Patient #1 Rheumatoid Arthritis Essentials For The Family Medicine Physician 45 y/o female Morning stiffness in her joints >1 hour Hands, Wrists, Knees, Ankles, Feet Polyarticular, symmetrical swelling
More informationLearning about Lupus. Learning About Lupus. Lupus Society of Illinois
Learning About Lupus Learning about Lupus Lupus Society of Illinois 525 W. Monroe Street, Suite 900 Chicago, Illinois 60661 Robert S. Katz, M.D. Professor of Medicine Rush University Medical Center Northwestern
More informationCoverage Criteria: Express Scripts, Inc. monograph dated 12/15/ months or as otherwise noted by indication
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Kineret (anakinra subcutaneous injection) Commercial HMO/PPO/CDHP
More informationMedical Management of Rheumatoid Arthritis (RA)
Medical Management of Rheumatoid Arthritis (RA) Dr Lee-Suan Teh Rheumatologist Royal Blackburn Hospital Educational objectives ABC Appreciate the epidemiology of RA Be able to diagnosis of RA Competent
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES HUMIRA PEDIATRIC
Generic Brand HICL GCN Exception/Other ADALIMUMAB HUMIRA 24800 HUMIRA PEDIATRIC GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Is the patient currently taking Humira? If
More informationPatient History Form Date of first appointment: / / Time of appointment: Birthplace: mm dd yyyy Name: Birthdate: / / LAST FIRST MIDDLE MAIDEN mm dd yyyy Address: STREET APT# Age: Sex: F M Telephone: H
More informationRegulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of:
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 8 Last Review Date: March 17, 2017 Simponi / Simponi
More informationRayos Prior Authorization Program Summary
Rayos Prior Authorization Program Summary FDA APPROVED INDICATIONS AND DOSAGE FDA-Approved Indications: 1 Agent Indication Dosage Rayos (prednisone delayedrelease tablet) as an anti-inflammatory or immunosuppressive
More information1 P a g e. Systemic Juvenile Idiopathic Arthritis (SJIA) (1.3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis.
LENGTH OF AUTHORIZATION: Initial: 3 months for Crohn s or Ulcerative Colitis; 1 year for all other indications. Renewal: 1 year dependent upon medical records supporting response to therapy and review
More informationPatient History Form
Date of first appointment: / / MONTH DA Y YEAR Name: Address: LAST STREET CITY MARITAL STATUS: Never Married Spouse/Significant Alive/Age EDUCATION (circle highest level attended): Time of appointment:
More informationNon-Steroidal Anti- Inflammatory Drugs. ATPE 410 Chapter 6
Non-Steroidal Anti- Inflammatory Drugs ATPE 410 Chapter 6 Inflammatory Process A normal, beneficial process that begins immediately after injury to facilitate repair and return the tissue to normal function
More informationDRUG THERAPY
www.pediatric-rheumathology.printo.it DRUG THERAPY NSAIDS NON-STEROIDAL ANTI-INFLAMMATORY DRUGS They are symptomatic anti-inflammatory, anti febrile (fever) and analgesic (pain reducing) medications. Symptomatic
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
Generic Brand HICL GCN Exception/Other GOLIMUMAB SIMPONI 22533, 22536, 34697, 35001 ROUTE = SUBCUTANE. GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Is the request for a
More informationPatient History Form
Patient History Form of first appointment: / / Time of appointment: Cell Phone: MONTH DA Y YEAR Name: Birthdate: / / LAST FIRST MIDDLE INITIAL MAIDEN MONTH DAY YEAR Address: Age: Sex: F M STREET APT# CITY
More informationNSAIDS & Drugs in Rheumatoid Arthritis (RA)
NSAIDS & Drugs in Rheumatoid Arthritis (RA) RA is a chronic progressive inflammation of joint lining with an autoimmune background against synovial membranes that can lead to joint destruction Affects
More informationNew Patient History Form Today s Date:
New Patient History Form Today s Date: MICHAEL L. MAWBY, MD MARIANNE PEACOCK, CNP 1115 S. Union Street Traverse City, MI 49684 Form Revised 1/18/2016 Name: Birthdate: (Last) (First) (MI) (Maiden) (MM/DD/YYYY)
More informationClinical Policy: Baricitinib (Olumiant) Reference Number: CP.PHAR.135 Effective Date: Last Review Date: 11.18
Clinical Policy: (Olumiant) Reference Number: CP.PHAR.135 Effective Date: 07.24.18 Last Review Date: 11.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationCimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.11 Subject: Cimzia Page: 1 of 5 Last Review Date: December 8, 2017 Cimzia Description Cimzia (certolizumab
More informationClinical Policy: Anakinra (Kineret) Reference Number: ERX.SPA.135 Effective Date:
Clinical Policy: (Kineret) Reference Number: ERX.SPA.135 Effective Date: 10.01.16 Last Review Date: 05.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationRheumatoid Arthritis. By: Hadi Esmaily (PharmD., BCCP, MBA) Department of Clinical Pharmacy, Shahid Beheshti Medical University
Rheumatoid Arthritis By: Hadi Esmaily (PharmD., BCCP, MBA) Department of Clinical Pharmacy, Shahid Beheshti Medical University Introduction RA is a Chronic, Systemic, Inflammatory disorder of unknown etiology
More informationCimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Cimzia Page: 1 of 5 Last Review Date: March 17, 2017 Cimzia Description Cimzia (certolizumab pegol)
More informationMedication Policy Manual. Topic: Otezla, apremilast Date of Origin: May 9, 2014
Medication Policy Manual Policy No: dru342 Topic: Otezla, apremilast Date of Origin: May 9, 2014 Committee Approval Date: January 19, 2015 Next Review Date: January 2016 Effective Date: April 1, 2015 IMPORTANT
More informationHelpline No:
ARTHRITIS FOUNDATION Registered Nonprofit Organisation - No. 002-847 NPO Helpline No: 0861 30 30 30 DRUGS AND ARTHRITIS This information leaflet is published by the Arthritis Foundation as part of our
More informationXeljanz (tofacitinib), Xeljanz XR (tofacitinib extended-release)
Market DC Xeljanz (tofacitinib), Xeljanz XR (tofacitinib extended-release) Override(s) Prior Authorization Quantity Limit Medications Xeljanz (tofacitinib) Approval Duration 1 year Quantity Limit May be
More informationPain or stiffness in joints after periods of inactivity or excessive use
Arthritis Awareness* Some older adults call it Arthur ; others refer to it as their constant compassion, but most describe it as extremely painful Arthritis is a chronic joint disease It is commonly believed
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: abatacept_orencia 4/2008 2/2018 2/2019 2/2018 Description of Procedure or Service Abatacept (Orencia ), a
More informationRemicade (infliximab) DRUG.00002
Applicability/Effective Date *- Florida Healthy Kids Remicade (infliximab) DRUG.00002 Override(s) Prior Authorization Step Therapy Medications Remicade (infliximab) Approval Duration 1 year Comment Intravenous
More informationLupus. Fast facts. What is lupus? What causes lupus? Who gets lupus?
Lupus Systemic lupus erythematosus, referred to as SLE or lupus, is sometimes called the "great imitator." Why? Because of its wide range of symptoms, people often confuse lupus with other health problems.
More informationLUPUS CAN DO EVERYTHING, BUT NOT EVERYTHING IS LUPUS LUPUS 101 SLE SUBSETS AUTOIMMUNE DISEASE 11/4/2013 HOWARD HAUPTMAN, MD IDIOPATHIC DISCOID LUPUS
LUPUS 101 LUPUS CAN DO EVERYTHING, BUT NOT EVERYTHING IS LUPUS HOWARD HAUPTMAN, MD IDIOPATHIC DISCOID LUPUS SLE SUBSETS SUBACUTE CUTANEOUS LUPUS DRUG INDUCED LUPUS NEONATAL LUPUS LATE ONSET LUPUS ANTI-PHOSPHOLIPID
More information10/25/2018. Autoimmunity and how to treat it. Disclosure. Why do we get autoimmunity? James Verbsky MD/PhD Pediatric Rheumatology/Immunology
Autoimmunity and how to treat it James Verbsky MD/PhD Pediatric Rheumatology/Immunology Disclosure None I will mention drug names and some brand names but I have no financial interest or any other ties
More informationInfliximab/Infliximab-dyyb DRUG.00002
Infliximab/Infliximab-dyyb DRUG.00002 Override(s) Prior Authorization Step Therapy Medications Remicade (infliximab) Inflectra (inflectra-dyyb) Approval Duration 1 year Comment Intravenous administration
More informationIntroduction. Rheumatoid Arthritis. Rheumatoid Arthritis. Arthritis vs Rheumatoid Arthritis
Rheumatoid Arthritis Stuart Weisman, MD Boulder Medical Center, P.C. 303-622-3724 Introduction What is rheumatoid arthritis? How is it different than arthritis? What are the symptoms? How is it diagnosed?
More informationAnalgesics. Munir Gharaibeh, MD, PhD, MHPE Faculty of Medicine The University of Jordan March, 2014
Analgesics Munir Gharaibeh, MD, PhD, MHPE Faculty of Medicine The University of Jordan March, 2014 Mar-14 Munir Gharaibeh, MD, PhD, MHPE 2 Feature Comparison of Analgesics Narcotic (Opioids) Nonnarcotic
More informationFirst Name. Specialty: Fax. First Name DOB: Duration:
Prescriber Information Last ame: First ame DEA/PI: Specialty: Phone - - Fax - - Member Information Last ame: First ame Member ID umber DOB: - - Medication Information: Drug ame and Strength: Diagnosis:
More informationCyltezo (adalimumab-adbm) CG-DRUG-64, CG-DRUG-65
Market DC Cyltezo (adalimumab-adbm) CG-DRUG-64, CG-DRUG-65 Override(s) Prior Authorization Quantity Limit Medications Cyltezo (adalimumab-adbm) 40 mg/0.8 ml prefilled syringe #* ^ Approval Duration 1 year
More informationA. Correct! Nociceptors are pain receptors stimulated by harmful stimuli, resulting in the sensation of pain.
Pharmacology - Problem Drill 19: Anti-Inflammatory and Analgesic Drugs No. 1 of 10 1. are pain receptors stimulated by harmful stimuli, resulting in the sensation of pain. #01 (A) Nociceptors (B) Histamines
More informationInflectra (infliximab-dyyb), Remicade (infliximab), Renflexis (infliximab-abda) DRUG CG-DRUG-64
Inflectra (infliximab-dyyb), Remicade (infliximab), Renflexis (infliximab-abda) DRUG.00002 CG-DRUG-64 Override(s) Prior Authorization *Washington Medicaid See State Specific Mandates Medications Inflectra
More informationElements for a Public Summary
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Osteoarthritis Osteoarthritis is the most common type of joint disease. It represents a group of conditions that result in changes
More information3. Has the patient shown improvement in signs and symptoms of the disease? Y N
Pharmacy Prior Authorization MERC CARE (MEDICAID) Renflexis (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax
More informationClinical Policy: Sarilumab (Kevzara) Reference Number: CP.PHAR.346 Effective Date: Last Review Date: 11.18
Clinical Policy: (Kevzara) Reference Number: CP.PHAR.346 Effective Date: 07.18.17 Last Review Date: 11.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationSimponi / Simponi ARIA (golimumab)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 6 Last Review Date: September 15, 2016 Simponi / Simponi
More informationClinical Policy: Abatacept (Orencia) Reference Number: ERX.SPA.123 Effective Date:
Clinical Policy: (Orencia) Reference Number: ERX.SPA.123 Effective Date: 10.01.16 Last Review Date: 05.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationPharmacology of Corticosteroids
Pharmacology of Corticosteroids Dr. Aliah Alshanwani Dept. of Pharmacology College of Medicine, KSU Feb 2018 1 The Corticosteroids are steroid hormones produced by the adrenal cortex. They consist of two
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
Generic Brand HICL GCN Exception/Other CERTOLIZUMAB PEGOL CIMZIA 35554 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Is the request for a patient with a diagnosis of moderate
More informationClinical Policy: Tofacitinib (Xeljanz, Xeljanz XR) Reference Number: ERX.SPA.110 Effective Date:
Clinical Policy: Tofacitinib (Xeljanz, Xeljanz XR) Reference Number: ERX.SPA.110 Effective Date: 10.01.16 Last Review Date: 05.18 Revision Log See Important Reminder at the end of this policy for important
More informationPatient History Form
Patient History Form Date of first appointment: / / Time of appointment: Birthplace: MONTH DA Y YEAR Name: Birthdate: / / LAST FIRST MIDDLE INITIAL MAIDEN MONTH DAY YEAR Address: Age: Sex: F M STREET APT#
More informationCoastal Arthritis and Rheumatism Associates PATIENT REGISTRATION
Coastal Arthritis and Rheumatism Associates PATIENT REGISTRATION Patient s Full Name: Last First Middle Home Phone: Sex: M F Date of Birth: / / Work Phone: Who is responsible for the bill? Home Address:
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC Update on the Treatment of Rheumatoid Arthritis Sabrina Fallavollita MDCM McGill University Canadian Society of Internal Medicine
More informationAdrenal Pharmacology
Adrenal Pharmacology Pharmacology Team Naim Kittana, Suhaib Hattab, Ansam Sawalha, Adham Abu Taha, Waleed Sweileh, Ramzi Shawahneh Faculty of Medicine & Health Sciences An-Najah National University 1 Steroidal
More informationNo destructive changes observed upon radiographic examination; radiographic evidence of osteoporosis is possible
Table 10.1. Progression of Rheumatoid Arthritis Stage 1 (early) Stage 2 (moderate) Stage 3 (severe) No destructive changes observed upon radiographic examination; radiographic evidence of osteoporosis
More informationRheumatology Therapeutics: Perioperative DMARD Management, Infection and Malignancy Risks, Vaccination Considerations. Heather Hansen, MD
Rheumatology Therapeutics: Perioperative DMARD Management, Infection and Malignancy Risks, Vaccination Considerations Heather Hansen, MD Objectives Know Broad Categories of Rheumatoid Arthritis Medications
More informationRheumatoid Arthritis. Module III
Rheumatoid Arthritis Module III Management: Biological disease modifying anti-rheumatic drugs, glucocorticoids and special situations (pregnancy & lactation) Dr Ved Chaturvedi MD, DM Senior Consultant
More informationSummary Article: Lupus (Systemic Lupus Erythematosus) from Harvard Medical School Health Topics A-Z
Topic Page: Systemic Lupus Erythematosus Summary Article: Lupus (Systemic Lupus Erythematosus) from Harvard Medical School Health Topics A-Z What Is It? Lupus is thought to develop when the immune system
More information2017 PERIOPERATIVE MEDICINE SYMPOSIUM Peri-operative use of immunosuppression in rheumatology patients
2017 PERIOPERATIVE MEDICINE SYMPOSIUM Peri-operative use of immunosuppression in rheumatology patients Dr Alberta Hoi Rheumatologist MBBS, FRACP, PhD NEW ERA IN MUSCULOSKELETAL MEDICINE New drugs - Biologics,
More information2. Does the patient have a diagnosis of ulcerative colitis or Crohn s? Y N
Pharmacy Prior Authorization AETA BETTER HEALTH LOUISIAA (MEDICAID) Remicade (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign
More informationAcetaminophen and NSAIDS. James Moriarity MD University of Notre Dame
Acetaminophen and NSAIDS James Moriarity MD University of Notre Dame Lecture Goals Understand the indications for acetaminophen and NSAID use in musculoskeletal medicine Understand the role of Eicosanoids
More informationClinical Policy: Anakinra (Kineret) Reference Number: CP.PHAR.244 Effective Date: Last Review Date: Line of Business: HIM, Medicaid
Clinical Policy: (Kineret) Reference Number: CP.PHAR.244 Effective Date: 08.16 Last Review Date: 11.18 Line of Business: HIM, Medicaid Coding Implications Revision Log See Important Reminder at the end
More informationEvolving therapies for posterior uveitis. Infliximab (Remicade) Infliximab: pharmacology. FDA-approved monoclonal antibody therapy Target
Evolving therapies for posterior uveitis Sam Dahr, M.D. September 17, 2005 Midwest Ophthalmology Conference Infliximab (Remicade) FDA approved for Crohn s disease, rheumatoid arthritis, and psoriatic arthritis
More informationHAQ-II(Health Assessment Questionnaire-II)
Kathy Karamlou, MD 355 Placentia Ave, suite 208 Newport Beach, CA 92663 949-631-6500 949-631-9700 NAME: DATE: DOB: HAQ-II(Health Assessment Questionnaire-II) We are interested in learning how your illness
More informationTo live with lupus, we need to know about lupus.
To live with lupus, we need to know about lupus. Zineb Aouhab, MD Assistant Professor of Medicine Loyola University Medical Center Division of Rheumatology 1 Where did the word lupus come from? The word
More informationPsoriatic Arthritis- Second Line Treatments
Psoriatic Arthritis- Second Line Treatments Second line treatments for Psoriatic Arthritis (PsA) are usually prescribed by a Rheumatologist, Dermatologist, or in a combined clinic where both the Dermatologist
More informationDr. Gina Del Giudice, M.D., FACR, FACP Michael J. Froncek, M.D., MS, FACP, FACR INITIAL PATIENT HISTORY AND HEALTH ASSESMENTS
Dr. Gina Del Giudice, M.D., FACR, FACP Michael J. Froncek, M.D., MS, FACP, FACR INITIAL PATIENT HISTORY AND HEALTH ASSESMENTS Please take a few minutes to fill out the information on all six pages as completely
More informationYou May Be at Risk. You are currently taking a non-steroidal anti-inflammatory drug (NSAID):
NSAIDS You May Be at Risk You are currently taking a non-steroidal anti-inflammatory drug (NSAID): Aspirin Diclofenac (Voltaren ) Diflunisal (Dolobid ) Etodolac (Lodine ) Ibuprofen (Advil ) Ketoprofen
More informationCorticosteroids. Hawler Medical University College of Medicine Department of Pharmacology and Biophysics Dr.Susan Abdulkadir Farhadi MSc Pharmacology
Corticosteroids Hawler Medical University College of Medicine Department of Pharmacology and Biophysics Dr.Susan Abdulkadir Farhadi MSc Pharmacology Objectives By the end of this lecture you should be
More informationRegional vs. Systemic Therapy. Corticosteroids. Regional vs. Systemic Therapy for Uveitis. Considerations
Regional vs. Systemic Therapy for Uveitis Nisha Acharya,, M.D., M.S. Director, Uveitis Service F.I. Proctor Foundation University of California, San Francisco December 4, 2010 No financial disclosures
More informationDental Management of the Organ or Stem Cell Transplant Patient
Dental Management of the Organ or Stem Cell Transplant Patient KEY POINTS Before and after organ or stem cell transplantation, patients require specialized dental management. Optimal dental management
More informationLast First Middle Initial Maiden Month/Day/Year. Address: Age: Sex: F M Street Apt. # Telephone: Home City State Zip Work
Patient History Form Date of first appointment: Time of appointment: Birthplace: Name: Birthdate: Last First Middle Initial Maiden Month/Day/Year Address: Age: Sex: F M Street Apt. # Telephone: Home City
More informationClinical Policy: Ustekinumab (Stelara) Reference Number: ERX.SPA.01 Effective Date:
Clinical Policy: (Stelara) Reference Number: ERX.SPA.01 Effective Date: 04.01.17 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationPharmacy Prior Authorization
Pharmacy Prior Authorization AETA BETTER HEALTH PESLVAIA & AETA BETTER HEALTH KIDS Humira (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: infliximab_remicade 5/2002 2/2017 2/2018 2/2017 Description of Procedure or Service Infliximab (REMICADE
More informationTreatment of Rheumatoid Arthritis: The Past, the Present and the Future
Treatment of Rheumatoid Arthritis: The Past, the Present and the Future Lai-Ling Winchow FCP(SA) Cert Rheum(SA) Chris Hani Baragwanath Academic Hospital University of the Witwatersrand Outline of presentation
More informationMedications Guide June 2017
s Guide June 2017 Arthritis Consumer Experts (ACE) produces its annual JointHealth Medications Guide to enable members/patients-at-large to have a meaningful conversation with their rheumatologist and
More informationWhy do ortho PTs need to know about pharmacology? Pharmacology for Orthopedic Physical Therapists. Pharmacology Defined: Pharmacology Defined:
Pharmacology for Orthopedic Physical Therapists Julie DeVahl, PT, MS Assistant Professor Department of Physical Therapy Why do ortho PTs need to know about pharmacology? Collaborative medical model Assist
More information